author_facet Dehghan-Kooshkghazi, Mahshid
Mathers, John C.
Dehghan-Kooshkghazi, Mahshid
Mathers, John C.
author Dehghan-Kooshkghazi, Mahshid
Mathers, John C.
spellingShingle Dehghan-Kooshkghazi, Mahshid
Mathers, John C.
British Journal of Nutrition
Starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the α-glucosidase inhibitor acarbose
Nutrition and Dietetics
Medicine (miscellaneous)
author_sort dehghan-kooshkghazi, mahshid
spelling Dehghan-Kooshkghazi, Mahshid Mathers, John C. 0007-1145 1475-2662 Cambridge University Press (CUP) Nutrition and Dietetics Medicine (miscellaneous) http://dx.doi.org/10.1079/bjn20031063 <jats:p>Acarbose (Glucobay®; Bayer) is an α-glucosidase inhibitor used to treat diabetes and which may have a role in the prevention of type 2 diabetes. The present study investigated the effects of acarbose treatment on the site and extent of starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation. Eighteen young male Wistar rats were fed ‘Westernised’ diets containing 0, 250 and 500mg acarbose/kg (six rats/diet) for 21d. For most variables measured, both acarbose doses had similar effects. Acarbose treatment suppressed starch digestion in the small bowel but there was compensatory salvage by bacterial fermentation in the large bowel. This was accompanied by a substantial hypertrophy of small- and large-bowel tissue and a consistent increase in crypt width along the intestine. Caecal total SCFA pool size was increased more than 4-fold, with even bigger increases for butyrate. These changes in butyrate were reflected in increased molar proportions of butyrate in blood from both the portal vein and heart. There was little effect of acarbose administration on crypt-cell proliferation (significant increase for mid-small intestine only). This is strong evidence against the hypothesis that increased fermentation and increased supply of butyrate enhances intestinal mucosal cell proliferation. In conclusion, apart from the increased faecal loss of starch, there was no evidence of adverse effects of acarbose on the aspects of large-bowel function investigated.</jats:p> Starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the α-glucosidase inhibitor acarbose British Journal of Nutrition
doi_str_mv 10.1079/bjn20031063
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA3OS9iam4yMDAzMTA2Mw
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA3OS9iam4yMDAzMTA2Mw
institution DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
imprint Cambridge University Press (CUP), 2004
imprint_str_mv Cambridge University Press (CUP), 2004
issn 0007-1145
1475-2662
issn_str_mv 0007-1145
1475-2662
language English
mega_collection Cambridge University Press (CUP) (CrossRef)
match_str dehghankooshkghazi2004starchdigestionlargebowelfermentationandintestinalmucosalcellproliferationinratstreatedwiththeaglucosidaseinhibitoracarbose
publishDateSort 2004
publisher Cambridge University Press (CUP)
recordtype ai
record_format ai
series British Journal of Nutrition
source_id 49
title Starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the α-glucosidase inhibitor acarbose
title_unstemmed Starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the α-glucosidase inhibitor acarbose
title_full Starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the α-glucosidase inhibitor acarbose
title_fullStr Starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the α-glucosidase inhibitor acarbose
title_full_unstemmed Starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the α-glucosidase inhibitor acarbose
title_short Starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the α-glucosidase inhibitor acarbose
title_sort starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the α-glucosidase inhibitor acarbose
topic Nutrition and Dietetics
Medicine (miscellaneous)
url http://dx.doi.org/10.1079/bjn20031063
publishDate 2004
physical 357-365
description <jats:p>Acarbose (Glucobay®; Bayer) is an α-glucosidase inhibitor used to treat diabetes and which may have a role in the prevention of type 2 diabetes. The present study investigated the effects of acarbose treatment on the site and extent of starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation. Eighteen young male Wistar rats were fed ‘Westernised’ diets containing 0, 250 and 500mg acarbose/kg (six rats/diet) for 21d. For most variables measured, both acarbose doses had similar effects. Acarbose treatment suppressed starch digestion in the small bowel but there was compensatory salvage by bacterial fermentation in the large bowel. This was accompanied by a substantial hypertrophy of small- and large-bowel tissue and a consistent increase in crypt width along the intestine. Caecal total SCFA pool size was increased more than 4-fold, with even bigger increases for butyrate. These changes in butyrate were reflected in increased molar proportions of butyrate in blood from both the portal vein and heart. There was little effect of acarbose administration on crypt-cell proliferation (significant increase for mid-small intestine only). This is strong evidence against the hypothesis that increased fermentation and increased supply of butyrate enhances intestinal mucosal cell proliferation. In conclusion, apart from the increased faecal loss of starch, there was no evidence of adverse effects of acarbose on the aspects of large-bowel function investigated.</jats:p>
container_issue 3
container_start_page 357
container_title British Journal of Nutrition
container_volume 91
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792345746776784904
geogr_code not assigned
last_indexed 2024-03-01T17:26:37.628Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Starch+digestion%2C+large-bowel+fermentation+and+intestinal+mucosal+cell+proliferation+in+rats+treated+with+the+%CE%B1-glucosidase+inhibitor+acarbose&rft.date=2004-03-01&genre=article&issn=1475-2662&volume=91&issue=3&spage=357&epage=365&pages=357-365&jtitle=British+Journal+of+Nutrition&atitle=Starch+digestion%2C+large-bowel+fermentation+and+intestinal+mucosal+cell+proliferation+in+rats+treated+with+the+%CE%B1-glucosidase+inhibitor+acarbose&aulast=Mathers&aufirst=John+C.&rft_id=info%3Adoi%2F10.1079%2Fbjn20031063&rft.language%5B0%5D=eng
SOLR
_version_ 1792345746776784904
author Dehghan-Kooshkghazi, Mahshid, Mathers, John C.
author_facet Dehghan-Kooshkghazi, Mahshid, Mathers, John C., Dehghan-Kooshkghazi, Mahshid, Mathers, John C.
author_sort dehghan-kooshkghazi, mahshid
container_issue 3
container_start_page 357
container_title British Journal of Nutrition
container_volume 91
description <jats:p>Acarbose (Glucobay®; Bayer) is an α-glucosidase inhibitor used to treat diabetes and which may have a role in the prevention of type 2 diabetes. The present study investigated the effects of acarbose treatment on the site and extent of starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation. Eighteen young male Wistar rats were fed ‘Westernised’ diets containing 0, 250 and 500mg acarbose/kg (six rats/diet) for 21d. For most variables measured, both acarbose doses had similar effects. Acarbose treatment suppressed starch digestion in the small bowel but there was compensatory salvage by bacterial fermentation in the large bowel. This was accompanied by a substantial hypertrophy of small- and large-bowel tissue and a consistent increase in crypt width along the intestine. Caecal total SCFA pool size was increased more than 4-fold, with even bigger increases for butyrate. These changes in butyrate were reflected in increased molar proportions of butyrate in blood from both the portal vein and heart. There was little effect of acarbose administration on crypt-cell proliferation (significant increase for mid-small intestine only). This is strong evidence against the hypothesis that increased fermentation and increased supply of butyrate enhances intestinal mucosal cell proliferation. In conclusion, apart from the increased faecal loss of starch, there was no evidence of adverse effects of acarbose on the aspects of large-bowel function investigated.</jats:p>
doi_str_mv 10.1079/bjn20031063
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA3OS9iam4yMDAzMTA2Mw
imprint Cambridge University Press (CUP), 2004
imprint_str_mv Cambridge University Press (CUP), 2004
institution DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229
issn 0007-1145, 1475-2662
issn_str_mv 0007-1145, 1475-2662
language English
last_indexed 2024-03-01T17:26:37.628Z
match_str dehghankooshkghazi2004starchdigestionlargebowelfermentationandintestinalmucosalcellproliferationinratstreatedwiththeaglucosidaseinhibitoracarbose
mega_collection Cambridge University Press (CUP) (CrossRef)
physical 357-365
publishDate 2004
publishDateSort 2004
publisher Cambridge University Press (CUP)
record_format ai
recordtype ai
series British Journal of Nutrition
source_id 49
spelling Dehghan-Kooshkghazi, Mahshid Mathers, John C. 0007-1145 1475-2662 Cambridge University Press (CUP) Nutrition and Dietetics Medicine (miscellaneous) http://dx.doi.org/10.1079/bjn20031063 <jats:p>Acarbose (Glucobay®; Bayer) is an α-glucosidase inhibitor used to treat diabetes and which may have a role in the prevention of type 2 diabetes. The present study investigated the effects of acarbose treatment on the site and extent of starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation. Eighteen young male Wistar rats were fed ‘Westernised’ diets containing 0, 250 and 500mg acarbose/kg (six rats/diet) for 21d. For most variables measured, both acarbose doses had similar effects. Acarbose treatment suppressed starch digestion in the small bowel but there was compensatory salvage by bacterial fermentation in the large bowel. This was accompanied by a substantial hypertrophy of small- and large-bowel tissue and a consistent increase in crypt width along the intestine. Caecal total SCFA pool size was increased more than 4-fold, with even bigger increases for butyrate. These changes in butyrate were reflected in increased molar proportions of butyrate in blood from both the portal vein and heart. There was little effect of acarbose administration on crypt-cell proliferation (significant increase for mid-small intestine only). This is strong evidence against the hypothesis that increased fermentation and increased supply of butyrate enhances intestinal mucosal cell proliferation. In conclusion, apart from the increased faecal loss of starch, there was no evidence of adverse effects of acarbose on the aspects of large-bowel function investigated.</jats:p> Starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the α-glucosidase inhibitor acarbose British Journal of Nutrition
spellingShingle Dehghan-Kooshkghazi, Mahshid, Mathers, John C., British Journal of Nutrition, Starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the α-glucosidase inhibitor acarbose, Nutrition and Dietetics, Medicine (miscellaneous)
title Starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the α-glucosidase inhibitor acarbose
title_full Starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the α-glucosidase inhibitor acarbose
title_fullStr Starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the α-glucosidase inhibitor acarbose
title_full_unstemmed Starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the α-glucosidase inhibitor acarbose
title_short Starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the α-glucosidase inhibitor acarbose
title_sort starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the α-glucosidase inhibitor acarbose
title_unstemmed Starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the α-glucosidase inhibitor acarbose
topic Nutrition and Dietetics, Medicine (miscellaneous)
url http://dx.doi.org/10.1079/bjn20031063